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To the Editor:
I have read with interest recent 
article Koshy et al.1 comparing several 
surgery-contained regimens with con-
current radiochemotherapy (RT-CHT). 
An intriguing finding is that concurrent 
RT-CHT achieved a median survival 
time (MST) of only (approximately) 
14 months (from the available survival 
curve) and a 5-year survival of only 
10.9%. Although the fact that patients 
have been treated in the modern era 
of three-dimensional conformal RT 
and concurrent CHT and in accredited 
institutions (by the American College 
of Surgeons), these figures seem to be 
very low for the developed world in 
comparison to what RT alone or with 
concurrent CHT has achieved over the 
past few decades. Interestingly, in the 
cohort of patients who survived for 
less than 4 months (presumably poor 
prognosis), majority of whom received 
RT-CHT, the MST was approximately 3 
months. Although this may have artifi-
cially influenced overall results, comor-
bidity did not attenuate the relationship 
between treatment and survival, as 
proven by the multivariate analysis.
However, concurrent RT-CHT 
has been reconfirmed as standard treat-
ment in inoperable (stage III) non–
small-cell lung cancer (NSCLC).2 In 
addition, recent data have shown that 
concurrent RT-CHT in clinical stage 
IIIA NSCLC patients offers excellent 
results accompanied with low toxic-
ity. Our recent study3 in 222 patients 
with favorable stage IIIA (no weight 
loss, Karnofsky Performance Status 
70–100) showed MST of 38 months 
and 5-year survival of 41% accompa-
nied with low toxicity (acute and late 
high-grade esophageal and broncho-
pulmonary toxicity observed in 7%, 
and 8% and in 7% and 3% patients, 
respectively) with no treatment-related 
deaths. Similar data were observed by 
MacManus et al.4 (4-year survival in 
stage IIIA patients, 32%).
These results seem superior to 
those of the most successful subgroups 
in the study by Koshy et al.1 where the 
best results were obtained with neod-
juvant RT-CHT followed by lobec-
tomy (5-year survival, 33.5%; MST 
estimated from the available survival 
curve, 30 months). In addition, they 
seem to be at least comparable with 
various neoadjuvant series including 
the best of the most favorable subgroup 
of patients in the study by Koshy et al. 
(patients achieving complete pathologi-
cal response after neoadjuvant RT-CHT: 
5-year survival, 40%).
Together with the failure of neod-
juvant RT-CHT and surgery to offer any 
benefit to patients with mostly stage 
IIIA, when compared with exclusive 
concurrent RT-CHT5,6 in prospective 
randomized clinical trials, these results 
clearly show that the direction where 
thoracic oncologists should go to opti-
mize treatment approaches in stage IIIA 
NSCLC is concurrent RT-CHT.
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The comments by Dr. Jeremic are 
appreciated. He states that a study show-
ing a 5-year overall survival of 41% 
in patients with favorable stage IIIA 
patients who received chemoradiation 
alone is evidence that chemoradiation 
alone should be the preferred approach.1 
However, the trial’s strict inclusion cri-
teria of patients with no weight loss 
and excellent performance status, both 
independent prognostic factors, were 
likely the driving force responsible 
for the impressive 5-year overall sur-
vival results, rather than the treatment 
received.2 Furthermore, in this study 
approximately 60% of the patients had 
a component of local failure. Therefore, 
in this population, surgical resection 
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